ATE168267T1 - Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten - Google Patents

Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten

Info

Publication number: ATE168267T1
Authority: AT; Austria
Prior art keywords: fatty acid; compositions containing; unsaturated fatty; cholesterol esters; containing cholesterol
Prior art date: 1993-01-06

Application number

AT93310599T

Other languages

English (en)

Inventor

David Frederick Horrobin

Original Assignee

Scotia Holdings Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-06

Filing date

1993-12-29

Publication date

1998-08-15

1993-12-29 Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc

1998-08-15 Application granted granted Critical

1998-08-15 Publication of ATE168267T1 publication Critical patent/ATE168267T1/de

Links

150000001840 cholesterol esters Chemical class 0.000 title 1
239000000203 mixture Substances 0.000 title 1
235000021122 unsaturated fatty acids Nutrition 0.000 title 1
150000004670 unsaturated fatty acids Chemical class 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 2
229930195729 fatty acid Natural products 0.000 abstract 2
239000000194 fatty acid Substances 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
-1 Cholesterol fatty acid esters Chemical class 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
235000004626 essential fatty acids Nutrition 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Fats And Perfumes (AREA)
Cosmetics (AREA)
Optical Recording Or Reproduction (AREA)
Medicinal Preparation (AREA)

AT93310599T 1993-01-06 1993-12-29 Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten ATE168267T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB939300125A GB9300125D0 (en)	1993-01-06	1993-01-06	Compositions containing esters of unsaturated fatty acids

Publications (1)

Publication Number	Publication Date
ATE168267T1 true ATE168267T1 (de)	1998-08-15

Family

ID=10728334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93310599T ATE168267T1 (de)	1993-01-06	1993-12-29	Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten

Country Status (17)

Country	Link
US (1)	US5604216A (de)
EP (1)	EP0606012B1 (de)
JP (1)	JPH06234644A (de)
KR (1)	KR940018088A (de)
CN (1)	CN1096197A (de)
AT (1)	ATE168267T1 (de)
AU (1)	AU673555B2 (de)
CA (1)	CA2112824A1 (de)
DE (1)	DE69319710T2 (de)
DK (1)	DK0606012T3 (de)
ES (1)	ES2119871T3 (de)
GB (1)	GB9300125D0 (de)
MY (1)	MY110765A (de)
NO (1)	NO940035D0 (de)
NZ (1)	NZ250583A (de)
RU (1)	RU2142468C1 (de)
ZA (1)	ZA9425B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6107499A (en) *	1988-02-26	2000-08-22	Neuromedica, Inc.	Dopamine analog amide
US5795909A (en) *	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) *	1996-05-22	2003-06-10	Protarga, Inc.	Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6153653A (en) *	1997-11-26	2000-11-28	Protarga, Inc.	Choline compositions and uses thereof
US5955459A (en) *	1997-11-26	1999-09-21	Neuromedica, Inc.	Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) *	1997-11-26	1999-11-02	Neuromedica, Inc.	Cholinergic compositions and uses thereof
US6197764B1 (en)	1997-11-26	2001-03-06	Protarga, Inc.	Clozapine compositions and uses thereof
US6149964A (en) *	1998-05-21	2000-11-21	Beech-Nut Nutrition Corporation	Egg yolk-containing baby food compositions and methods therefor
US7141266B2 (en) *	1998-05-21	2006-11-28	Beech-Nut Nutrition Corporation	Baby-food compositions enhancing visual acuity and methods therefor
US6579551B1 (en)	1998-05-21	2003-06-17	Beech-Nut Nutrition Corporation	Baby-food compositions containing egg yolk and methods therefor
US7413759B2 (en) *	1998-05-21	2008-08-19	Beech-Nut Nutrition Corporation	Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
NZ333817A (en) *	1998-08-25	2000-09-29	Mcneil Ppc Inc	Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
US5892068A (en) *	1998-08-25	1999-04-06	Mcneil-Ppc, Inc.	Preparation of sterol and stanol-esters
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
AU2006201772B2 (en) *	1999-01-27	2010-02-04	Amarin Neuroscience Limited	Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
US7235583B1 (en)	1999-03-09	2007-06-26	Luitpold Pharmaceuticals, Inc.,	Fatty acid-anticancer conjugates and uses thereof
EP1175901B1 (de) *	1999-04-15	2006-05-31	Kaneka Corporation	Agonisten des peroxisom aktivator-responsiven rezeptors
JP2000355538A (ja) *	1999-04-15	2000-12-26	Kanegafuchi Chem Ind Co Ltd	ペルオキシゾーム活性化剤応答性受容体アゴニスト
AU6813700A (en) *	1999-08-30	2001-03-26	Ocean Nutrition Canada Ltd.	A nutritional supplement for lowering serum triglyceride and cholesterol levels
US6998501B1 (en) *	1999-08-30	2006-02-14	Ocean Nutrition Canada Limited	Nutritional supplement for lowering serum triglyceride and cholesterol levels
US20030206958A1 (en) *	2000-12-22	2003-11-06	Cattaneo Maurizio V.	Chitosan biopolymer for the topical delivery of active agents
DK1121928T3 (da) *	2000-01-31	2008-03-17	Haerting S A	Sammensætninger indeholdende phytosterol- og policosanolestere af fedtsyrer til reduktion af niveauet af blodcholesterol og -triglycerider
KR20010091499A (ko) *	2000-03-16	2001-10-23	김용범	레이저 그래픽 디스플레이 장치
JP4594489B2 (ja) *	2000-03-31	2010-12-08	備前化成株式会社	特異的殺癌細胞剤及びこれを配合してなる組成物
EP1427407A4 (de)	2001-03-23	2005-05-11	Luitpold Pharm Inc	Fettamin-arzneimittel-konjugate
ES2387562T3 (es) *	2001-03-23	2012-09-26	Luitpold Pharmaceuticals, Inc.	Conjugados alcohol graso-medicamento
JP2003048831A (ja) *	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10154221A1 (de) *	2001-11-07	2003-05-15	Max Delbrueck Centrum	Mittel zur Behandlung von Läsionen des Nervensystems
US20050123500A1 (en) *	2003-01-31	2005-06-09	The Procter & Gamble Company	Means for improving the appearance of mammalian hair and nails
MXPA05008216A (es) *	2003-01-31	2005-10-05	Procter & Gamble	Medios para mejorar la apariencia del tejido queratinoso mamifero.
WO2004089969A2 (en) *	2003-04-02	2004-10-21	The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services	Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
EP1637134A4 (de) *	2003-06-20	2010-01-27	Mochida Pharm Co Ltd	Zusammensetzung zur prävention/behandlung von varizen
CA2436650A1 (en) *	2003-08-06	2005-02-06	Naturia Inc.	Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US20060141046A1 (en) *	2004-05-06	2006-06-29	Ivrea Pharmaceuticals, Inc.	Particles for the delivery of active agents
AU2005240189A1 (en) *	2004-05-06	2005-11-17	Ivrea Pharmaceuticals, Inc.	Particles for the delivery of active agents
BRPI0613358A8 (pt) *	2005-07-08	2017-12-26	Dsm Ip Assets Bv	ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
US20080110624A1 (en) *	2005-07-15	2008-05-15	Halliburton Energy Services, Inc.	Methods for controlling water and particulate production in subterranean wells
ITMI20052377A1 (it) *	2005-12-13	2007-06-14	Anna Petroni	Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
FR2902659A1 (fr) *	2006-06-23	2007-12-28	Pierre Fabre Medicament Sa	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2010028067A1 (en)	2008-09-02	2010-03-11	Amarin Corporation Plc	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR101383006B1 (ko)	2009-02-10	2014-04-08	아마린 파마, 인크.	고중성지방혈증 치료 방법
SG175390A1 (en)	2009-04-29	2011-12-29	Amarin Corp Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt)	2009-04-29	2020-11-19	Amarin Pharmaceuticals Ie Ltd	Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh)	2009-06-15	2016-11-09	阿马里纳药物爱尔兰有限公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CN102656153B (zh) *	2009-10-29	2015-02-18	延世大学校产学协力团	新型血管渗漏阻断剂
NZ778131A (en)	2010-11-29	2023-03-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
EP2775837A4 (de)	2011-11-07	2015-10-28	Amarin Pharmaceuticals Ie Ltd	Verfahren zur behandlung von hypertriglyceridämie
ES2891473T3 (es)	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP4338805B1 (de)	2012-06-29	2025-06-04	Amarin Pharmaceuticals Ireland Limited	Eicosapentaensäureethylester zur verwendung bei der verringerung des risikos eines nicht-fatalen herzinfarktes bei einer person in statin-therapie
US9717741B2 (en)	2012-10-11	2017-08-01	Anaplasi Pharmaceuticals Llc	Method and compositions for treating psoriasis
ES2660978T3 (es) *	2012-10-11	2018-03-26	Anaplasi Pharmaceuticals Llc	Método y composiciones para el tratamiento de la psoriasis
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6224203B2 (ja) *	2016-12-08	2017-11-01	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するための組成物
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP6491293B2 (ja) *	2017-10-04	2019-03-27	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko)	2018-09-24	2021-09-09	애머린 파마슈티칼스 아일랜드 리미티드	대상체에서 심혈관 사건의 위험도를 감소시키는 방법
JP6728425B2 (ja) *	2019-02-28	2020-07-22	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するためのクリーム、ローション、又はゲルの組成物
US12427134B2 (en)	2019-11-12	2025-09-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en)	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0073834B1 (de) *	1981-03-13	1986-06-25	Green Cross Corporation	Wasserlösliche cholesterolabkömmlinge
GB8524275D0 (en) *	1985-10-02	1985-11-06	Efamol Ltd	Pharmaceutical & dietary compositions
SU1456442A1 (ru) *	1987-04-03	1989-02-07	Житомирский Государственный Педагогический Институт Им.И.Франко	(Холестерилоксикарбонилметил)трифенилфосфонийхлорид в качестве полупродукта в синтезе холестериловых эфиров непредельных карбоновых кислот

1993
- 1993-01-06 GB GB939300125A patent/GB9300125D0/en active Pending
- 1993-12-23 NZ NZ250583A patent/NZ250583A/xx unknown
- 1993-12-29 ES ES93310599T patent/ES2119871T3/es not_active Expired - Lifetime
- 1993-12-29 DE DE69319710T patent/DE69319710T2/de not_active Expired - Fee Related
- 1993-12-29 AT AT93310599T patent/ATE168267T1/de not_active IP Right Cessation
- 1993-12-29 EP EP93310599A patent/EP0606012B1/de not_active Expired - Lifetime
- 1993-12-29 DK DK93310599T patent/DK0606012T3/da active
- 1993-12-30 AU AU52763/93A patent/AU673555B2/en not_active Ceased
1994
- 1994-01-04 MY MYPI94000009A patent/MY110765A/en unknown
- 1994-01-04 ZA ZA9425A patent/ZA9425B/xx unknown
- 1994-01-05 CA CA002112824A patent/CA2112824A1/en not_active Abandoned
- 1994-01-05 NO NO940035A patent/NO940035D0/no unknown
- 1994-01-05 RU RU94000061A patent/RU2142468C1/ru active
- 1994-01-06 US US08/178,553 patent/US5604216A/en not_active Expired - Fee Related
- 1994-01-06 JP JP6000338A patent/JPH06234644A/ja active Pending
- 1994-01-06 CN CN94100242A patent/CN1096197A/zh active Pending
- 1994-01-06 KR KR1019940000159A patent/KR940018088A/ko not_active Ceased

Also Published As

Publication number	Publication date
GB9300125D0 (en)	1993-03-03
ZA9425B (en)	1994-08-19
AU5276393A (en)	1994-07-14
NZ250583A (en)	1997-08-22
AU673555B2 (en)	1996-11-14
ES2119871T3 (es)	1998-10-16
CN1096197A (zh)	1994-12-14
DE69319710D1 (de)	1998-08-20
US5604216A (en)	1997-02-18
NO940035L (de)	1994-07-07
DK0606012T3 (da)	1999-04-19
EP0606012B1 (de)	1998-07-15
DE69319710T2 (de)	1999-03-11
MY110765A (en)	1999-03-31
NO940035D0 (no)	1994-01-05
KR940018088A (ko)	1994-08-16
CA2112824A1 (en)	1994-07-07
EP0606012A1 (de)	1994-07-13
JPH06234644A (ja)	1994-08-23
RU2142468C1 (ru)	1999-12-10

Legal Events

Date	Code	Title	Description
1999-05-15	UEP	Publication of translation of european patent specification
2000-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69319710D1 (de)	1998-08-20	Zusammensetzungen, die Cholesterin Ester von ungesättigten Fettsäure enthalten
RU94000061A (ru)	1995-08-27	Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция
ATE106867T1 (de)	1994-06-15	13-trans-retinsäureester.
TW429145B (en)	2001-04-11	Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
AU7053494A (en)	1995-01-03	Method of treating coronary vascular disease using docosahexaenoic acid
ATE208608T1 (de)	2001-11-15	Kosmetische oder dermatologische zusammensetzung, die ein alpha-hydroxysäure, salicylsäure und ein retinoid enthalten
NO940277L (no)	1994-07-28	Triglycerider og blandinger av slike
CA2144312A1 (en)	1994-04-14	Unsaturated aliphatic dicarboxylic acids
DE69312579D1 (de)	1997-09-04	Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit
ATE138639T1 (de)	1996-06-15	L-carnitin- und alkanoyl-l-carnitin-ester mit glykolsäure oder ihre ester und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von dermatosen
AU1821888A (en)	1989-01-05	Treatment or prevention of memory loss using essential fatty acid compositions
DE69302098D1 (de)	1996-05-09	Zusammensetzungen von hexitan-fettsäureestern
DE59504267D1 (de)	1998-12-24	Härten von ungesättigten fetten, fettsäuren oder fettsäureestern
AU554413B2 (en)	1986-08-21	Linoleic acid and essential fatty acid compositions as
DE3760876D1 (en)	1989-11-30	Cyclohexane-, cyclohexene- and cyclohexadiene, bicycloû2.2.1¨heptane and bicyclo û2.2.1¨heptenecarboxylic acid esters, and also perfume compositions and perfumed products which contain one or more of said compounds as perfume component
DE3784738D1 (de)	1993-04-15	Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
ATE113291T1 (de)	1994-11-15	Polyaromatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.
ES2191671T3 (es)	2003-09-16	Esteres de 1,4-dihidropiridina 4-fenil-3-sustituidos.
DE3851937D1 (de)	1994-12-01	Nicht gesättigte cycloaliphatische Ester von makroliden Antibiotika und linkosamiden Antibiotika, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen und kosmetischen Zusammensetzungen.
RU94002319A (ru)	1995-12-27	Триглицериды